Celecoxib in arthritis: relative risk management profile and implications for patients

Gayle McKellar¹
Gurkirpal Singh²

¹Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, UK; ²Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA, USA

Abstract: Celecoxib is a selective cyclo-oxygenase 2 inhibitor licensed for use in musculoskeletal symptoms as well as in primary dysmenorrhea and acute pain. One advantage celecoxib has over traditional nonsteroidal anti-inflammatory drugs is that of significantly fewer gastrointestinal side-effects associated with its use. Much has been published on the potential cardiovascular and cerebrovascular complications of its administration. This review details the available evidence to allow prescribers to make informed decisions in the light of potentially conflicting evidence. The overall cardiovascular risk is increased with higher doses of celecoxib but is comparable with nonselective nonsteroidal anti-inflammatory use. As with all of these drugs, the potential cardiovascular and gastrointestinal risks of prescription need to be weighed up against possible benefits for each individual patient and discussed with the patients themselves.

Keywords: arthritis, cardiovascular, celecoxib, gastrointestinal, nonsteroidal anti-inflammatory drugs, safety

Introduction

Celecoxib (Celebrex®; Pfizer Inc.) was the first selective cyclo-oxygenase (COX) 2 inhibitor to be used in everyday clinical practice. It is approved for use for musculoskeletal symptoms in osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis, as well as in the management of primary dysmenorrhea and acute pain. The advantages for selective COX2 inhibitor use has been well-documented in the literature; similar efficacy to nonsteroidal anti-inflammatory drugs (NSAIDs) but with less gastrointestinal (GI) side-effects. Celecoxib was the first of many selective COX2 inhibitors most of which have now been withdrawn from clinical use (lumiracoxib rofecoxib and valdecoxib) because of concerns of serious side-effects. This review will discuss the evidence for the potential benefits of celecoxib use as well as scrutinizing the studies which detail its possible deleterious effects.

Clinical effectiveness in treating arthritis

Multiple clinical trials have demonstrated that celecoxib has similar efficacy as nsNSAIDs in the management of pain and inflammation, both acute and chronic. Emery et al in 1999¹ studied the efficacy of celecoxib in patients with RA. Three hundred twenty-six patients received celecoxib 200 mg twice daily and 329 received diclofenac, a NSAID, 75 mg twice daily for 24 weeks. There was no documented difference between the 2 drugs for physician’s assessment, patient assessment, number of swollen or tender joints, visual analogue scale (VAS) pain score, early morning stiffness, or C-reactive protein (CRP). The mean number of swollen and tender joints...
did however decrease over the course of the study. ACR-20 response at 24 weeks was scored as 25% in the celecoxib group and 22% in the diclofenac group. This paper was one of the initial studies to give credence to the use of celecoxib where traditional NSAIDs would have been used for the treatment of arthritis symptoms. In the same year a second group undertook a randomized, placebo-controlled, double-blind trial with approximately 200 patients in each arm. Placebo was compared with naproxen 500 mg twice daily, celecoxib 100 mg twice daily, 200 mg twice daily, or 400 mg twice daily. Celecoxib produced a significant improvement in signs and symptoms of RA for all efficacy measures with maximal effects by 2 weeks and comparable with the benefits seen with naproxen. Withdrawals for treatment failure were lower for all active therapy groups than for placebo ($P < 0.001$).

A few years later, Deeks et al performed a systematic review of the efficacy of celecoxib compared with another nonselective (ns) NSAID or placebo. Over 15,000 patients with either OA or RA who had received at least 12 weeks of therapy were identified. Efficacy was measured by the WOMAC score (Western Ontario and McMaster Osteoarthritis Index) and tolerability by rates of withdrawal for adverse events. Celecoxib and NSAIDs were equally effective for all efficacy outcomes. There were far fewer withdrawals in those taking celecoxib than other NSAIDs for GI side-effects.

A recently published review of celecoxib assessed the clinical and cost-effectiveness of selective COX2 inhibitors and NSAIDs for OA and RA treatment. Forty randomized controlled trials involving celecoxib compared to placebo, other selective COX2 inhibitors, or nonselective (ns) NSAIDs were identified. Compared with nsNSAIDs, celecoxib was equally efficacious and of superior GI tolerability. The base-case incremental cost per quality adjusted life year (QALY) results for celecoxib versus diclofenac was £151,000.

**Celecoxib and the upper gastrointestinal system**

The GI toxicity of traditional NSAIDs is due to the nonselective inhibition of both COX1 and COX2 isoenzymes involved in prostaglandin synthesis. Selective COX2 inhibitors were developed to suppress prostaglandin production by the COX2 enzyme selectively, consequently, giving anti-inflammatory and analgesic benefits while protecting the gastroprotective activity of COX1. The clinical adverse GI effects of NSAIDs are well known. Clinical symptoms are poor predictors of actual gastrointestinal injury. Anti-inflammatory drug-induced peptic ulcers are frequently asymptomatic. Patients taking traditional NSAIDs were previously said to be 5 to 7 times more likely to be hospitalized for a GI complication than nonusers.

One of the first studies on the potential lesser upper GI effects of celecoxib was published in 1999. Patients with RA were randomized to one of three differing doses of celecoxib (100 mg, 200 mg or 400 mg twice daily), naproxen or placebo. All doses of celecoxib were seen to have a reduced frequency of endoscopic ulcers than naproxen, the comparative NSAID in this study. Emery et al demonstrated significantly reduced reporting of abdominal pain, gastric ulceration and duodenal ulceration when celecoxib was compared with diclofenac ($P < 0.05$, $P < 0.001$, and $P < 0.009$, respectively).

The celecoxib long-term arthritis safety study (CLASS) was a large double-blind randomized controlled trial. Patients with OA or RA were randomized to receive celecoxib 400 mg twice daily ($n = 3987$), ibuprofen 800 mg 3 times daily ($n = 1985$) or diclofenac 75 mg twice daily ($n = 1996$). Initial data (at 6 months follow up) suggested that rates of symptomatic GI ulcers and ulcer complications were significantly lower with celecoxib compared with NSAIDs. However, full study results, when made available, showed that there was no difference at 1 year. The CLASS study had a high-dropout rate at 1 year which made the interpretation of these results somewhat difficult.

In 2002, Mamdani et al performed a retrospective observational cohort study to compare rates of upper GI hemorrhage in elderly patients prescribed NSAIDs and selective COX2 inhibitors who were previously anti-inflammatory naïve. They found no increased short-term risk with celecoxib (adjusted rate ratio 1.0, 95% confidence interval [CI] 0.7 to 1.6), unlike NSAIDs and rofecoxib. The risk of upper GI hemorrhage with celecoxib was similar to that of controls not using NSAIDs. Singh et al compared the GI side-effects of celecoxib with diclofenac and naproxen in a double-blinded, randomized clinical trial of over 13,000 patients (SUCCESS-I). Significantly more ulcer complications were seen in the NSAID than celecoxib group (0.8/1000-person years versus 0.1/1000-person years, odds ratio [OR] 7.02, $P = 0.008$).

van der Linden et al performed a nested case-control study of a historical cohort of patients in The Netherlands to assess the incidence of first hospitalization for GI events in patient prescribed traditional NSAIDs and selective COX2 inhibitors (incorporating gastric and duodenal ulcers, ulceration of GI tract, gastritis, duodenitis, and GI hemorrhage). Adjusted OR for any GI with celecoxib therapy was 1.36 (95% CI 0.70 to 2.66). When compared with celecoxib, unsurprisingly, the risk was much higher with
the traditional NSAIDs, naproxen (OR 3.26, 95% CI 1.59 to 6.70) and diclofenac (OR 3.50, 95% CI 1.76 to 6.98).

Management difficulties can arise when patients are admitted with a GI bleed but require anti-inflammatory management for musculoskeletal symptoms. Chan et al published on recurrent ulcer bleeding rates in patients subsequently given celecoxib, who were initially admitted with upper GI bleeding while on a traditional NSAID for arthritis treatment. Patients were either given celecoxib plus placebo or esomperazone, a proton-pump inhibitor (PPI). The combination group had a significantly reduced incidence of upper GI bleeding: 0 vs 12%, $P = 0.0004$, 95% CI 4.1 to 13.7.

**Potential prevention of colorectal malignancies with celecoxib**

The APC study investigators investigated the potential benefits of celecoxib on reducing colorectal adenomatous polyps and cancer. This was on the basis that selective COX2 inhibitors had been shown to reduce the number of colorectal adenomas in animals, as well as that the over expression of COX2 had been associated with colorectal adenomatous polyps and cancer. Patients who had previously had adenomas were randomized to placebo, celecoxib 200 mg twice daily or 400 mg twice daily. The estimated cumulative incidence of detection of adenomas at year 3 was 43.2% in the 200 mg twice daily group (risk ratio [RR] 0.67, 95% CI 0.59 to 0.77, $P < 0.001$) and 37.5% in the 400 mg twice daily group (RR 0.55, 95% CI 0.48 to 0.64, $P < 0.001$) compared with placebo. For advanced adenomas in the two treatment groups the estimated cumulative incidence was 7.8% (RR 0.43, 95% CI 0.31 to 0.61, $P < 0.001$) and 6.3% (RR 0.34, 95% CI 0.24 to 0.50, $P < 0.001$) respectively.

In the same issue of the NEJM, the PreSAP trial investigators reported their randomized placebo controlled trial. They demonstrated that the use of 400 mg celecoxib once daily significantly reduced the occurrence of colorectal adenomas within the 3 years after a polypectomy (relative risk 0.64, 95% CI 0.56 to 0.75 $P < 0.001$).

**Potential hepatic side-effects**

A number of individual case reports have been published detailing hepatotoxicity secondary to celecoxib treatment. More impressive however are the published data on larger-scale investigatory groups such as the CLASS study where nearly 4000 patients took celecoxib at 800 mg/day without any significant elevation in aminotransferases compared with traditional NSAID. Importantly, the SUCCESS-1 study showed that the occurrence of transaminitis was much lower with celecoxib than with non-NSAIDs, 0.5% versus 1.3% ($P < 0.001$). The FDA and WHO published a case/noncase analysis of spontaneous reports of hepatotoxicity of COX2s versus nonNSAIDs. The authors concluded that there was no increased safety concerns for celecoxib compared with NSAIDs, unlike diclofenac and nimesulide. While we should be alert to the potential development of abnormal liver function while a patient is taking celecoxib, the major studies do not show any noteworthy trend.

**Celecoxib and acute myocardial infarction**

Concern was initially raised of the potential cardiovascular (CV) toxicity of selective COX2 inhibitors and NSAIDs was raised by the publication of data from the VIGOR trial by Bombardier et al. The CV risk of rofecoxib at that time was explained by being artefactual because of a presumed cardioprotective benefit of naproxen. Subsequent observational studies proved that this could not be true. The first firm evidence demonstrating the increased risk of selective COX2 inhibitors compared with placebo was the APPROVe trial in 2004. The results of this trial confirmed many previous observational studies on the CV risks of rofecoxib and lead to the withdrawal of the drug. Subsequently, the APC and Pre-SAP studies showed that at high doses, celecoxib can also increase the risk of CV complications when compared to placebo.

The risk of high doses of celecoxib was confirmed in a pooled analysis published by Solomon et al. The data from 7950 patients enrolled in 6 placebo-controlled trials of celecoxib was analyzed. There was a clear increased risk of all CV events including acute myocardial infarction (AMI) with increasing doses of celecoxib ($P = 0.0005$). It should be noted that the patients in these studies had conditions other than arthritis. Many observational studies have shown that the increase in risk is not limited to celecoxib, but indeed is present with most non-NSAIDs and that the risk with celecoxib may be of smaller magnitude than most other NSAIDs. There are a large number of observational studies in publication in which these conclusions are also borne out.

As mentioned previously, a large amount of data related to celecoxib and AMI is available from studies investigating the potential benefits in colorectal neoplasia prevention. The first data were published by Solomon et al in 2005. Deaths from CV causes and nonfatal AMI numbered 27 in patients exposed to celecoxib, calculated hazard ratio (HR)
3.4 (nonfatal AMI alone numbered 18). A further paper published by Bertagnolli et al. the following year analyzed CV “disorders”, encompassing a variety of conditions including AMI, angina, cerebrovascular disease, and circulatory collapse. RR in the whole group for low-dose celecoxib was 1.5, compared with 1.8 in higher doses.

The much referenced systematic review and meta-analysis from McGettigan and Henry analyzed the risk of serious CV events with selective COX2 inhibitor therapy. They found that celecoxib was not associated with an increased risk of vascular occlusion (summary RR 1.06, 95% CI 0.91 to 1.23). This compares with summary RR of 1.33 for low-dose rofecoxib (95% CI 1.00 to 1.79), 2.19 for high-dose rofecoxib (95% CI 1.64 to 2.91), 1.40 for diclofenac (95% CI 1.16 to 1.70), 1.07 for ibuprofen (95% CI 0.97 to 1.18), and 0.97 for naproxen (95% CI 0.97 to 1.18).

As detailed from the many published works on this topic, the data on potential increased cardiovascular risk for patients taking celecoxib are inconsistent. It would seem clinically appropriate for the decision on prescription to be made on a patient by patient basis taking into account the individual’s CV history and risk profile, and with regular reviews of the need for therapy. While inconsistent, the evidence most likely points to an increase in risk of AMI with celecoxib compared to placebo when doses of at least 400 mg are used. No clinical trials have been able to show an increased risk when 200 mg/day or less is used, although this does not rule out such an effect in susceptible patients. The increased risk does not seem to be out of proportion to the risk seen with nsNSAIDs.

Celecoxib and heart failure
Anti-inflammatory drugs can be associated with a degree of fluid retention through an increased cortical expression of COX2. Mamdani’s population-based retrospective cohort study assessed nearly 19000 NSAID-naïve patients who were commenced on celecoxib. Less than 1% developed congestive heart failure (CHF) within 6 months of commencement (identical to nonNSAID control group) and approximately 6% developed CHF over a 5-year period (not significant compared to the control group).

A population-based retrospective cohort study studied 2256 patients aged over 66 who were prescribed NSAID, rofecoxib or celecoxib after an index admission for CHF. Crude event rates for recurrent CHF per 100 person-years were calculated and showed a difference between selective COX2 inhibitors (celecoxib 27.6, rofecoxib 32.4) and NSAIDs (24.4). Within the Colorectal Adenoma Prevention trial

Potential renal side-effects
The physiological interactions between COX2 and the renal system is complex. Increased cortical expression of COX2 is seen with sodium depletion, aortic coarctation, CHF, loop diuretic therapy and Bartter’s syndrome amongst others. COX2 expression is specifically linked to the renin-angiotensin system (RAS) and causes activation of this pathway. Decreased RAS activity causes increased COX2 expression and vice versa. COX2 is known to have critical roles at the cortical thick ascending limb of the loop of Henle, macula densa and in the medullary interstitium. There is case-report documentation of renal side-effects secondary to celecoxib use, but much more robust data are available from a number of large-scale studies and reviews.

A randomized crossover trial of celecoxib with naproxen as the comparator looked specifically at renal function outcomes in an elderly population. A comparable reduction in glomerular filtration rate was seen for both naproxen and celecoxib and therefore the selective COX2 inhibitor was not felt to be any more nephrotoxic. Similarly, the CLASS study did not show any significant elevation in serum creatinine in nearly 4000 celecoxib users when compared with NSAID users (ibuprofen or diclofenac). Zhang et al published a large meta-analysis of 114 randomized, double-blind controlled trials of selective COX2 inhibitors, within which 37 celecoxib trial populations were identified. The RR of developing renal dysfunction with celecoxib was 0.61 (95% CI 0.4 to 0.94) compared with controls. No between-treatment difference in creatinine clearance or serum electrolytes was seen in a double-blind, placebo-controlled study of 85 patients assigned to naproxen, etoricoxib, or celecoxib.
As per prescribing guidelines, the use of celecoxib and NSAIDs is contra-indicated in patients with pre-existing renal impairment. The prescribing physician should remain alert to the development of abnormal renal function in a patient prescribed celecoxib, but its use is not associated with any increased nephrotoxicity compared with traditional NSAIDs.

**Blood pressure effects of celecoxib**

The effects of the addition of celecoxib on blood pressure (BP) control in patients on angiotension-converting enzyme inhibitors for hypertension has been studied via 24-hour ambulatory BP monitoring. Doses of celecoxib 200 mg twice daily made no difference on the anti-hypertensive effect of lisinopril. Wolfe et al have published data on the association of NSAID use with hypertension.

In normotensive and hypertensive patients, there was no increased OR of higher documented BP with celecoxib. This was not the case for rofecoxib. Zhang’s meta-analysis also failed to show any increased RR of hypertension with celecoxib therapy: 0.83.

A number of meta-analyses have scrutinized the potential evidence connecting celecoxib with a rise in blood pressure. Aw et al published a meta-analysis in 2005 of 19 randomized control trials, which included 8 celecoxib trial populations. Weighted mean differences (WMD) of systolic and diastolic BPs were calculated. Overall, a disproportionate increase in systolic rather than diastolic BP was seen with all nNSAIDs. The overall RR of developing hypertension for celecoxib compared with placebo was not statistically significant (0.81, 95% CI 0.13 to 5.21). These data on hypertension compares well with the only other selective COX2 inhibitor still on the market, etoricoxib.

The CRESCENT investigators, lead by Sowers, did not show any difference with celecoxib on 24-hour ambulatory BP control in known hypertensives. However, the proportion of patients with controlled blood pressure at baseline who developed worsening of BP by week 6 was documented as 16% in the celecoxib arm (P = 0.05), indicating that like all NSAIDs, BP monitoring is advised whenever treatment is initiated with celecoxib. Bertagnolli’s work on the potential role in colorectal adenoma prevention of celecoxib documented some blood pressure data. There was no significant increased RR of developing hypertension in the cohort and aspirin co-prescription made no difference. In contrast, Schwartz et al demonstrated a significant increase in ambulatory systolic BP with etoricoxib 90 mg once daily compared with celecoxib 200 mg twice daily and naproxen 500 mg twice daily (P < 0.05). Additionally, recently published data from the MEDAL study documented an increase in systolic BP (average rise of 3.4 to 3.6 mmHg) with etoricoxib therapy.

**Celecoxib and stroke**

Within the Colorectal Adenoma Prevention trial, the number of nonfatal strokes with the placebo group was identical to the events in the celecoxib 200 mg twice daily group (n = 3, 0.4%), compared with 5 events (0.7%) in the celecoxib 400 mg twice daily group. Solomon et al’s cohort study of over 26,000 celecoxib users in the Medicare program identified 988 strokes and an adjusted RR of 1.00 (95% CI 0.92 to 1.09).

A landmark study from Andersohn and colleagues assessed nearly 500,000 patients on the UK GP research database between 2000 and 2004 to identify the risk of ischemic stroke with NSAID or selective COX2 inhibitor use. No increased risk was found with current celecoxib use (multivariate OR 1.07). An increased risk was seen with rofecoxib and etoricoxib (OR 1.71 and 2.38, respectively). As per the AMI data, a dose-dependent effect was seen. Celecoxib at ≤200 mg/day was associated with a multivariate OR 0.97 (95% CI 0.71 to 1.32) and >200 mg/day was associated with a multivariate OR 1.20 (95% CI 0.46 to 3.11). Etoricoxib at ≤60 mg/day was associated with a much higher multivariate OR 2.04 (95% CI 0.87 to 4.80) and >60 mg/day was associated with a multivariate OR 3.27 (95% CI 0.59 to 18.16). It is possible that these differences in stroke rates between celecoxib and etoricoxib reflect the differential effect on hypertension of these drugs.

Lee et al reviewed the impact of celecoxib prescription on cerebrovascular disease incidence in patients with and without documented coronary artery disease (CAD). There was no increased risk of cerebrovascular event in the group without CAD prescribed celecoxib (OR 0.97, 95% CI 0.68 to 1.37). However, there was an increased risk of events in those with pre-existing CAD prescribed celecoxib (OR 1.40, 95% CI 0.96 to 2.03). A recently published study based on data from the population-based Rotterdam study assessed HR for ischemic stroke with NSAID and selective COX2 inhibitor prescription. Only 1 event was documented in celecoxib users and therefore there was no significant outcome.

Nadareishvili et al performed a nested case control analysis to determine the risk of stroke in patients with RA. Two hundred sixty-nine patients with first-ever stroke were identified, including 41 in patients with RA. The OR for
ischemic stroke in RA was 2.66 (95% CI 1.24 to 5.70, \( P = 0.012 \)). Adjusted for cardiovascular, RA risk factors, and other co-variants, ischemic stroke was significantly associated with rofecoxib use (OR 3.66, \( P = 0.27 \)), but not significantly with celecoxib (OR 2.65, \( P = 0.051 \)). A recently published retrospective cohort study of over 300,000 Medicaid patients in Tennessee over a 5-year period documented 4354 stroke admissions. Of these, 144 were patients who were prescribed celecoxib. Compared with nonusers of selective COX2 inhibitors or NSAIDs, the adjusted HR for stroke was only 1.04 (95% CI 0.87 to 1.23). A slightly higher HR of 1.12 (95% CI 0.83 to 1.52) in new users of celecoxib was documented.

**Effects of co-prescription of celecoxib and aspirin**

The benefit of aspirin in the primary and secondary prevention of CV events is well established. As the prescription rates for aspirin will continue to climb, the number of patients potentially prescribed this as well as an anti-inflammatory drug will too.

Wilner et al published a double-blind, placebo-controlled trial of 16 healthy volunteers assigned to celecoxib 400 mg daily or placebo for 4 days. Aspirin 325 mg plus celecoxib 200 mg or placebo was prescribed on day 5. No significant difference in thromboxane inhibition between the 2 groups was noted. There was also no significant difference in the effect of aspirin on platelet aggregation due to ADP, collagen, or arachidonic acid between the groups. The groups summarized that celecoxib does not have an effect on the aspirin effects of platelet function. This is an important consideration in the selection of NSAIDs in patients on low-dose aspirin since, unlike celecoxib, several nNSAIDs have been shown to cause pharmacodynamic interference with the anti-platelet effect of aspirin.

The population impact of any possible interaction is potentially large. In a sample of the general population prescribed selective COX2 inhibitors, analyzed by Cox et al 48% were co-prescribed aspirin, 43% paracetamol, and, interestingly, 10% also were prescribed a nonselective NSAID. Unsurprisingly, the use of aspirin increased with increasing patient age.

Levesque documented the RR of first AMI in a cohort of over 113,000 elderly patients. Patients prescribed celecoxib with or without aspirin were identified. There was no significant difference in adjusted RR of AMI in those who were or were not prescribed aspirin alongside celecoxib. This differs from the low-dose rofecoxib group who showed a significantly reduced risk of AMI if prescribed aspirin – the same was not true for patients on high-dose rofecoxib. It must be pointed out that the actual number of patients who had an AMI while on aspirin was small and conclusions drawn from this study should be guarded. Rahme et al found that the combination of celecoxib and aspirin was less likely to be associated with hospitalization for GI events than NSAIDs with aspirin (HR 0.62, 95% 0.48 to 0.80). In fact, hospitalization rates for GI events were similar for celecoxib plus aspirin as NSAID without aspirin (HR 1.01, 95% CI 0.81 to 1.25). A limitation of the study was that over-the-counter data for aspirin were not available.

**Conclusion**

Celecoxib continues to be an effective and valuable alternative to traditional NSAIDs in the treatment of acute and chronic pain. The superior GI tolerability is well-documented and compelling. Data on potential increased CV risk for patients taking celecoxib are inconsistent, but do point to a small increase risk, especially when higher doses are prescribed. This risk is comparable with that of traditional nonselective NSAIDs.

As with all of these drugs, the potential CV and GI risks of prescription need to be weighed against possible benefits for each individual patient and discussed with the patient. If the CV risk increase with celecoxib is small and lower than that of most other NSAIDs, the concern would be of increasing the complications in a high CV risk patient if they were to be prescribed another NSAID. If such a high-risk patient must take aspirin, the argument for selective COX2 inhibitors is stronger as nNSAIDs may block the effect of aspirin. Concomitant PPI use should be considered in these patients. As is the case with all anti-inflammatories, the prescription of celecoxib for an individual patient should be reviewed regularly and the lowest dose used for the shortest possible period of time.

**Disclosures**

The authors declare no conflicts of interest.

**References**


